期刊文献+

红曲有效成分洛伐他汀对高脂小鼠血脂代谢及脂蛋白脂酶mRNA表达的作用 被引量:19

Effect of Lovastatin from Red Kojic on lipid metabolism and expression of lipoprotein lipase mRNA in hyperlipidemic mice
下载PDF
导出
摘要 目的探讨红曲有效成分洛伐他汀对高脂小鼠血脂代谢调节的分子机制。方法昆明种雌性小鼠48只,按血清总胆固醇(TC)分为A、B、C、D、E、F 6组:正常对照组、高脂对照组、绞股蓝总苷阳性对照组、洛伐他汀低、中、高(5、15、30 mg/kg)剂量组。A组喂饲基础饲料,其他各组喂饲高脂饲料;按剂量分别ig给药6周,禁食12 h后,测定小鼠血脂水平相关指标;用Trizol试剂法提取总RNA,用反转录聚合酶链反应(RT-PCR)法检测肝、脾组织脂蛋白脂酶(LPL)mRNA的表达。结果实验6周末,洛伐他汀低、中、高各剂量组使小鼠动脉硬化指数(AI)均极显著低于高脂组(P<0.01);洛伐他汀中、高剂量组和绞股蓝总苷阳性对照组使高脂小鼠血清TC、甘油三酯(TG)、低密度脂蛋白-胆固醇(LDL-C)均极显著低于高脂组(P<0.01);洛伐他汀低、中、高剂量组与高脂组相比,显著升高血清高密度脂蛋白-胆固醇(HDL-C)(P<0.01);洛伐他汀低、中、高剂量组均提高肝组织中LPLmRNA的表达,且呈剂量依赖关系。结论洛伐他汀通过促进LPL mRNA转录而调节高脂小鼠血清血脂代谢水平,这可能是其调节血脂,预防动脉粥样硬化(AS)等心脑血管疾病的机制之一。 Objective To study the effect of Lovastatin from Red Kojic on lipid metabolism in mice fedhigh-fat diet and its anti-hyperlipidemic molecular mechanism. Methods According to serum TC level, 48female mice were randomly divided into six groups: A-normal control group; B-high-fat control group; C-Gypenosides (20 mg/kg) positive control group; D, E, F-Lovastatin 5, 15, and 30 mg/kg groups. GroupA was fed basic diet and the other groups were fed high-fat diet for six weeks. Groups A and B were ignormal water, group C was ig Gypenosides 20 mg/kg, and groups D, E, F were ig Lovastatin 5, 15, and30 mg/kg, respectively. Blood lipid levels were determined after 12 h-starvation. The mRNA expressionof lipoprotein lipase (LPL) in liver and spleen was detected by reverse transcription polymerase chain reac-tion (RT-PCR). Results Serum TC, TG, and LDL-C level were significantly lower in groups C, E, Fthan in group B, group D was lower than group B, but there was not significantly different at the end ofsix weeks. Serum HDL-C levels were significantly higher in groups D, E, F than in group B. AI was sig-nificantly lower in groups D, E, F than in group B. Lovastatin increased the expression of LPL mRNA inliver dose-dependently. Conclusion It is suggested that Lovastatin could modulate blood lipid by promot-ing mRNA expression of LPL in liver. This may be one important mechnaism of Lovastatin to modulateblood lipid and prevent atherosclerosis (AS).
出处 《中草药》 CAS CSCD 北大核心 2005年第5期713-717,共5页 Chinese Traditional and Herbal Drugs
基金 湖北省自然科学基金项目(2002AB080)
  • 相关文献

参考文献12

  • 1LiJZ HeSL WangHL.血栓病学[M].Bejing: Science Press,1988..
  • 2Blomhoff J P. Lipoproteins, lipases, and the metabolic cardiovascular syndrome [J]. J Cardiovasc Pharmacol, 1992,20 (Suppl 8): 22-25.
  • 3Gehrisch S. Common mutations of the lipoprotein lipase gene and their clinical significance [J]. Curt Atheroscler Rep,1999, 1(1): 70-78.
  • 4Endo A. Monacolin K, a new hypocholesterolemic agent produced by Monascus species[J]. J Antibiotics, 1979, 32 (8):852-854.
  • 5Moti L K, Mark E M, Kathleen B. Long-term safety and once-daily niacin/lovastatin formulation for patients with dyslipidemia [J]. Am J Cardiol, 2002, 89 (6) : 672-678.
  • 6Jone R D, Michael C, Tyroler H A. Air force/texas coronary atherosclerosis prevention study (afcaps/texcaps) : Additional perspectives on tolerability of long-term treatment with lovastatin [J]. Am J Cardiol, 2001, 87 (9): 1074-1079.
  • 7迟家敏,张剑峰,边延涛,孙美珍,杜风和,许毓申,季福绥,李宏然,许峰,秦明照,何青.国产洛伐他汀治疗原发性高胆固醇血症的临床研究[J].中国全科医学,2000,3(5):360-362. 被引量:5
  • 8张红宇,高菊珍.云南省产洛伐他汀降胆固醇作用的实验研究[J].云南医药,1999,20(5):373-374. 被引量:4
  • 9包旭,包定元,李建农.国产洛伐他汀(Lovastatin)调血脂作用的实验观察[J].华西药学杂志,1996,11(1):32-34. 被引量:4
  • 10ZhouJ.保健食品设计原理及其应用[M].Beijing: China Light Industrial Publishing House,1998..

二级参考文献11

共引文献6

同被引文献277

引证文献19

二级引证文献157

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部